Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance, with 12% revenue growth and improved margins. The company projects continued growth through new product launches and market expansions. Despite regulatory and market expansion risks, the optimistic guidance and strategic initiatives, such as increased R&D and capital expenditures, suggest positive sentiment. The absence of negative sentiment in the Q&A further supports this view. Overall, the positive financial results and forward-looking strategies indicate a likely positive stock price movement in the short term.
Key Financial Performance
Revenue $45.2 million, a 12% increase year-over-year, driven by strong demand for our flagship product and expansion into new markets.
Gross Margin 68%, up from 65% in the prior year, due to improved operational efficiencies and cost management.
Net Income $5.8 million, a 20% increase year-over-year, attributed to higher revenue and better cost control.
Operating Expenses $18.4 million, a 5% increase year-over-year, primarily due to increased investment in research and development.
Research and Development Expenses $7.2 million, a 10% increase year-over-year, reflecting our commitment to innovation and product pipeline expansion.
Cash Flow from Operations $12.6 million, a 15% increase year-over-year, supported by improved profitability and working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that its forward-looking statements regarding regulatory filings and approvals are subject to risks and uncertainties, which could impact their ability to expand into new markets or achieve planned clinical trial outcomes.
Market Expansion Challenges: Expansion into new markets is highlighted as a focus area, but it is accompanied by risks and uncertainties that could hinder successful entry or growth in these markets.
Clinical Trial Risks: The company's clinical trial plans and timing are subject to uncertainties, which could delay or impact the outcomes necessary for product development and market approval.
Financial Performance Risks: Forward-looking statements about expected financial and operating performance are subject to risks that could lead to material deviations from projected results.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Research and Development Activities: The company is focusing on advancing its research and development activities, which may include new clinical trials and product innovations.
Clinical Trial Plans and Timing: Plans to initiate new clinical trials and provide updates on the timing of these trials.
Regulatory Filings: Expected to make regulatory filings related to new products and market expansions.
Expansion into New Markets: Plans to expand into new geographical markets to increase market share.
Business Development Opportunities: Exploring new business development opportunities to enhance growth.
Expected Financial and Operating Performance: Projections for financial growth and improved operating performance in the upcoming quarters.
Revenue Expectations: The company expects revenue growth driven by new product launches and market expansion.
Margin Projections: Anticipates improved margins due to cost optimization strategies and increased sales volume.
Capital Expenditures: Plans to increase capital expenditures to support research and development and market expansion.
Market Trends: Expects favorable market trends in the health and wellness sector to drive demand for its products.
Business Segment Performance: Forecasts strong performance in key business segments, particularly in new markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anderson Canaccord
Assistant afternoon
Bioscience Inc
Bioscience press
CEO Director
Canaccord Genuity
Capital LLC
Dezellem Tieton
Director CFO
Division Anderson
Division Dezellem
Division Sean
Dr
EDT Ladies
Fried CEO
Genuity Corp
Jan Farmhouse
Jeffrey Cohen
LLC Jan
LLC PM
Niagen Bioscience
Officer Jeffrey
PM EDT
QA today
Research Division
Research LLC
activity trial
development activity
expansion market
expectation today
gentleman Niagen
opportunity statement
section Niagen
statement expectation
today Niagen
today reminder
NAGE Transcript
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call reveals strong financial performance, with 12% revenue growth and improved margins. The company projects continued growth through new product launches and market expansions. Despite regulatory and market expansion risks, the optimistic guidance and strategic initiatives, such as increased R&D and capital expenditures, suggest positive sentiment. The absence of negative sentiment in the Q&A further supports this view. Overall, the positive financial results and forward-looking strategies indicate a likely positive stock price movement in the short term.
Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights strong financial performance with a 30% YoY revenue growth and improved net income and gross margin. The company has no debt and substantial cash reserves, indicating financial stability. Positive factors include a new partnership expanding distribution, a conservative yet confident guidance, and a $10 million share buyback plan. Although there are some uncertainties, such as legal issues with the FDA, the overall sentiment is positive, driven by strong financials and strategic growth initiatives.
Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call shows strong financial performance, with significant revenue growth and improved net income. The strategic partnership and strong balance sheet are positive indicators. Despite some uncertainties in the Q&A, such as the new partnership's feedback and rollout timelines, the overall sentiment is positive due to the optimistic outlook on margins and potential market expansion. The absence of debt and increased cash flow bolster the positive sentiment. Without market cap data, a precise prediction is challenging, but overall indicators suggest a positive impact on the stock price.
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript
Positive5-14
The earnings call presented robust financial performance with a 38% revenue increase and a $5.1 million net income. The company has a strong cash position with no debt and has initiated a $10 million share buyback program. Despite some regulatory uncertainties, the strong growth in e-commerce and ingredient business, coupled with strategic market expansion plans, and positive product reception indicate a strong positive sentiment. The lack of market cap data suggests potential for a strong stock price reaction.
NAGE Slides
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
